Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) and Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.
Profitability
This table compares Lipella Pharmaceuticals and Conduit Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lipella Pharmaceuticals | -882.82% | -192.33% | -154.24% |
| Conduit Pharmaceuticals | N/A | N/A | -328.67% |
Analyst Ratings
This is a summary of current recommendations for Lipella Pharmaceuticals and Conduit Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lipella Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| Conduit Pharmaceuticals | 0 | 0 | 0 | 1 | 4.00 |
Valuation & Earnings
This table compares Lipella Pharmaceuticals and Conduit Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lipella Pharmaceuticals | $483,533.00 | 7.93 | -$4.62 million | ($4.25) | -0.75 |
| Conduit Pharmaceuticals | N/A | N/A | -$540,000.00 | N/A | N/A |
Conduit Pharmaceuticals has lower revenue, but higher earnings than Lipella Pharmaceuticals.
Insider and Institutional Ownership
74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 30.9% of Conduit Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Lipella Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 2.31, indicating that its stock price is 131% more volatile than the S&P 500.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
